Gastroenterology
Volume 135, Issue 3 , Pages 821-829 , September 2008

Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C

  • Sarah Maylin

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • INSERM U-773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France
    • ,
  • Michelle Martinot–Peignoux

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • INSERM U-773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France
    • ,
  • Rami Moucari

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    • ,
  • Nathalie Boyer

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    • ,
  • Marie–Pierre Ripault

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    • ,
  • Dominique Cazals–Hatem

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    • Service d'Anatomie-Cytologie Pathologique, Hôpital Beaujon, Clichy, France
    • ,
  • Nathalie Giuily

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    • ,
  • Corinne Castelnau

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    • ,
  • Ana Carolina Cardoso

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    • ,
  • Tarik Asselah

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • Service d'Hépatologie, Hôpital Beaujon, Clichy, France
    • ,
  • Cyrille Féray

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • INSERM U-773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France
    • ,
  • Marie Hélène Nicolas–Chanoine

      Affiliations

    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • INSERM U-773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France
    • ,
  • Pierre Bedossa

      Affiliations

    • Service d'Anatomie-Cytologie Pathologique, Hôpital Beaujon, Clichy, France
    • INSERM U-773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France
    • ,
  • Patrick Marcellin

      Affiliations

    • Université Paris VII, Hôpital Beaujon, Clichy, France
    • Service de Microbiologie, Hôpital Beaujon, Clichy, France
    • INSERM U-773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France
    • Corresponding Author InformationAddress reprint requests to: Patrick Marcellin, INSERM, U-773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Université Paris VII, and Service d'Hépatologie, Hôpital Beaujon, 92110 Clichy, France. fax: (331) 4730-9440

Received 1 August 2007 ,Accepted 15 May 2008.

References 

  1. National Institutes of Health. Management of hepatitis C: 2002. http://consensus.nih.gov/2002/2002HepatitisC2002116html.htmAccessed: March 20, 2006
  2. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C (The 2002 French consensus). Gut. 2003;52:1784–1787
  3. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426–1432
  4. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492
  5. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666–1672
  6. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680
  7. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395–403
  8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  10. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  11. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875–881
  12. Lau DT, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28:1121–1127
  13. Reichard O, Glaumann H, Fryden A, et al. Long-term follow-up of chronic hepatitis C patients with sustained virologic response to alpha-interferon. J Hepatol. 1999;30:783–787
  14. McHutchison JG, Poynard T, Esteban-Mur R, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology. 2002;35:688–693
  15. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virologic response to interferon monotherapy. Gut. 2004;53:1504–1508
  16. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313
  17. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-relates cirrhosis (A retrospective study). Hepatology. 2007;45:579–587
  18. Willems M, Peerlinck K, Moshage H, et al. Hepatitis C virus-RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: evidence for viral replication in peripheral blood mononuclear cells. J Med Virol. 1994;42:272–278
  19. Lerat H, Berby F, Trabaud MA, et al. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest. 1996;97:845–851
  20. Lerat H, Rumin S, Habersetzer F, et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood. 1998;91:3841–3849
  21. Goutagny N, Fatmi A, De Ledinghen V, et al. Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis. 2003;187:1951–1958
  22. Ducoulombier D, Roque-Afonso AM, Di Liberto G, et al. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology. 2004;39:817–825
  23. Roque-Afonso AM, Ducoulombier D, Di Liberto G, et al. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol. 2005;79:6349–6357
  24. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41:106–114
  25. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, et al. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis. 2006;43:1277–1283
  26. Pham TN, MacParland SA, Mulrooney PM, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004;78:5867–5874
  27. Giannini C, Giannelli F, Zignego AL. Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. (letter) Hepatology. 2006;43:1166–1167
  28. Romeo R, Pol S, Berthelot P, et al. Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med. 1994;121:276–277
  29. Shindo M, Arai K, Sokawa Y, et al. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann Intern Med. 1995;122:586–591
  30. Moreno M, Perez-Alvarez R, Rodrigo L, et al. Long-term evolution of liver histopathology in patients with chronic hepatitis C and sustained response. J Viral Hepat. 2005;97:860–869
  31. Bedossa P, Poynard T METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289–293
  32. Comanor L, Anderson F, Ghany M, et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol. 2001;96:2968–2972
  33. Hofmann WP, Dries V, Herrmann E, et al. Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue. J Clin Virol. 2005;32:289–293
  34. Tedeschi RM, Pivette E, Zanussi S, et al. Quantification of Hepatitis C virus (HCV) in liver specimens and sera from patients with human immunodeficiency virus coinfection by using the Versant HCV RNA 3.0 (branched DNA-based) DAN assay. J Clin Microbiol. 2003;41:3046–3050
  35. Germer JJ, Najewski DW, Rosser M, et al. Evaluation of the trugene HCV 5' NC genotyping kit with the new GeneLibrarian module 3.1.2 for genotyping of hepatitis C virus from clinical specimens. J Clin Microbiol. 2003;41:4855–4857
  36. Sarrazin C, Teuber G, Kokka R, et al. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology. 2000;32:818–823
  37. Gerotto M, Dal Pero F, Bortoletto G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol. 2006;44:83–87
  38. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1356–1358
  39. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517–524
  40. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–1758
  41. Bizollon T, Ahmed SN, Radenne S, et al. Long term histologic improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 2003;52:283–287

PII: S0016-5085(08)00865-2

doi: 10.1053/j.gastro.2008.05.044

Gastroenterology
Volume 135, Issue 3 , Pages 821-829 , September 2008

Article Tools

* Image Usage & Resolution